IMPORTANCE Postmarket evidence generation for medical devices is important yet limited for prosthetic aortic valve devices in the United Kingdom.
Heart Valve Registry fulfilled an important role: the ability to monitor trends in outcomes by different prosthetic valve models. It was setup to do this by recording valve model and serial numbers for implanted prosthetic valves and also by linkage to mortality data, including cause of death, from the Office for National Statistics. In 2004, funding was withdrawn owing to cost and governance issues, with its functionality partly subsumed by a national adult cardiac surgery register. 12 Currently, the UK agency responsible for ensuring that medical devices meet applicable standards of safety-the Medicines and Healthcare products Regulatory Agency (MHRA)-collects data on acute valve failures submitted by health care professionals; however, in the absence of a device-specific registry, the opportunity to detect patterns of unexpected outcomes is limited. Prospective surveillance based on clinical registries that record device-specific information can identify important signals that passive reporting mechanisms may miss, 13, 14 and there have been calls to move from reactive to proactive monitoring. 14 As a prelude to any prospective surveillance program, we present results for a retrospective cross-sectional analysis of prosthetic valves implanted into patients undergoing aortic valve replacement (AVR) surgery with or without concomitant coronary artery bypass grafting in England and Wales over the past 15 years.
Methods

Extraction and Preprocessing of Aortic Valve Surgery Data
A complete extract from the National Adult Cardiac Surgery Audit (NACSA; registry version 4.1.2), which is run by the National Institute for Cardiovascular Outcomes Research (NICOR; an institute of University College London), was performed on October 10, 2014. This extract included all adult cardiac surgery procedures performed in UK National Health Service (NHS) hospitals, some private hospitals and some hospitals in the Republic of Ireland. Case ascertainment of NHS procedure is expected to be high for most of the study period. 12 As part of a wider clinical epidemiological research and quality improvement program, a regularly updated suite of "data cleaning" rules developed by specialist clinicians were coded and applied to the raw data (excluding the valve model data) prior to any analysis as summarized in eAppendix 1 in the Supplement. 15, 16 This study was approved by the NICOR NACSA Research Board, and the need to obtain informed consent from patients was waived as patient identifiable information was either removed or pseudonymized. The initial filtering step was to extract all records corresponding to aortic valve surgery performed in hospitals located in England and Wales between April 1, 1998, and March 31, 2013. Data for 1 private hospital were removed prior to analysis pending local validation, as were all data for patients who had more than 1 record in the registry for the same admission spell. For the purposes of this study, we selected all patients who underwent an AVR with or without coronary artery bypass grafting. We then excluded all records corresponding to: (1) patients having previous cardiac surgery; (2) suspected incorrectly entered transcatheter aortic valve implantation (TAVI) procedures (as identified using a rules-based approach); (3) emergency or salvage procedures; (4) unidentifiable responsible consultant surgeon (as identified by a unique surgeon's General Medical Council number in the registry); (5) missing primary outcome data.
Record Linkage
To facilitate long-term monitoring of patient and valve status, we performed multiple record linkages for each patient for life status, surgical reoperation, and TAVI as described in eAppendix 1 in the Supplement.
Study Variables
For each procedure, data were extracted for administrative factors, patient characteristics, comorbidities, surgical team, intraoperative factors, and postoperative outcomes. There were few missing clinical data (all >95% complete with the exception of the dichotomous creatinine variable [5. 6% missing], critical preoperative state [7. 4% missing], hemodynamics [5.1% missing] , and aortic valve pathology [10.1% missing]). Details of study variable definitions and missing data imputation are given in eAppendix 2 in the Supplement.
Study Outcomes
The outcome for this study was time from surgery to the first event of death or reintervention. Patients were censored at the last follow-up time if alive and reintervention free. Patients who died in hospital on the day of surgery were recorded as having a nominal survival time of 0.5 days. Follow-up data, until the point of discharge, were collected by the NACSA registry, and postdischarge survival data were collected by record linkage to the Office for National Statistics death registry. Reintervention was defined as surgical reoperation on the aortic valve for any reason or TAVI. Time-to-reintervention data was collected by intrarecord and interrecord linkage as described above.
Statistical Analysis
Mechanical and biological valves were analyzed separately to avoid confounding by indication. Valves were compared only at series level. The Kaplan-Meier estimator was used to construct survival curves for the time-to-event outcome and compared between valves using log-rank tests. Multivariable Cox proportional hazards regression models were used to adjust for potential differences with zero-mean valve series-level normally distributed random effects. The exponentiated randomeffects-also known as the shared frailties-act multiplicatively on the baseline hazard rate and therefore have an intuitive translation: frailty terms greater than 1 correspond to increased hazard for a valve, and those less than 1 correspond to decreased hazard. Frailties where the corresponding 95% prediction interval lower limit lies above 1 indicate a valve with a significantly large hazard rate for the outcome. The focus of this study was not the identification of prognostic factors, hence we limit reporting to the frailty effects. For comparison, unadjusted frailties are also reported. All analyses and data cleaning were performed in R version 3.3.1 (R Foundation for Statistical Computing; http://www.R-project.org/). A more detailed description of the statistical analysis is given in eAppendix 1 in the Supplement. A number of different sensitivity analyses were performed (eAppendix 1 in the Supplement). All inferences remained broadly consistent.
Results
From 79 345 AVR with or without coronary artery bypass grafting records with a biological or mechanical prosthesis, a total of 54 866 records were retained for analysis ( Figure 1 ; eAppendix 2 in the Supplement), from 37 hospitals (including 4 private units) and 344 consultant surgeons. eTable 1 in the Supplement lists the valves included, which were grouped into 15 and 10 series of biological and mechanical valves, respectively. Figure 2 shows an increasing trend in the implantation rate of biological valves during the study period, stabilizing at 86%. Figure 3 shows the number of valves implanted by time for each series. The distribution of patient age at surgery (Figure 4) indicates homogeneity between the valve series within type (biological and mechanical), with the exception of greater patient ages for the Medtronic Hall series, Vascutek (including Koehler Medical and AorTech) Ultracor series, Edwards Lifesciences mechanical series, and Sorin Sutureless series relative to others of the same type. Plots for logistic EuroSCORE, sex, native valve pathology, procedure, left ventricular ejection fraction, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), valve size, and This line graph demonstrates an increase in biological prosthesis implantation rates from 59% to 86% over the study period. 
Valve Outcomes
During a median follow-up of 4.1 years (maximum follow-up 15.3 years), 13 104 deaths (11 353 biological; 1751 mechanical) were recorded and there were 723 reinterventions (571 biological; 152 mechanical; 682 were surgical procedures and 41 were TAVIs). Results from the Kaplan-Meier estimator analysis and pathological data for surgical reinterventions are described in the eAppendix in the Supplement.
After adjustment, the random effects survival model indicated that the Sorin Mitroflow series (frailty, 1.19; 95% prediction interval [PI], 1.09-1.31]) and Sorin Biological series (frailty, 1.18; 95% PI, 1.06-1.32) displayed larger hazard than expected ( Figure 5 ). To place the outcomes into perspective, the 10-year overall freedom from reintervention or death rates for the 2 valves were 33.8% (95% CI, 31.3%-36.5%) and 41.4% (95% CI, 37.6%-45.6%), respectively, compared with the overall average of 47.2% (95% CI, 46.2%-48.1%) for all non-Sorin biological valves. Although nonsignificant, the lower 95% PI for the Medtronic ATS-3f series only marginally crossed the line of unity (frailty, 1.21; 95% PI, 1.00-1.47]). For mechanical valves, the Medtronic Hall valve had a significantly larger unadjusted hazard (unadjusted frailty, 1.48; 95% PI, 1.22-1.80). However, after adjustment this was diminished (adjusted frailty, 1.10; 95% PI, 0.97-1.24), reflecting the greater patient age relative to the profile of other mechanical valves. Additional results are provided in the eAppendix in the Supplement.
There were 3 prosthetic valves with a significant reduction in hazard ( A subgroup analysis of all bioprosthesis records performed on or after April 1, 2008, (n = 23 834) showed that the lower 95% PI limit was less than 1 for every valve after adjustment (eAppendix in the Supplement).
Discussion
We analyzed a comprehensive clinical registry to measure reintervention-free survival in a large series of patients undergoing AVR in the United Kingdom. Two series of prosthetic aortic valves were associated with significantly increased hazards of death or reintervention, relative to the population of prosthetic valves implanted in England and Wales from large suppliers. Similarly, 3 series of prosthetic valves were associated with decreased hazards. Inferences remained broadly consistent following covariate adjustment and sensitivity analyses. This study has shown that routinely collected clinical registry data can be exploited, in conjunction with multifaceted record linkage, to perform long-term device surveillance. There is a large literature examining outcomes following different prosthetic AVR implants. Few studies, however, reflect national data. Moreover, the evidence base is mixed. For example, some studies have suggested an inferior performance of the Sorin Mitroflow 17,18 whereas others have demonstrated long-term durability and hemodynamic performance.
19,20
The National Health Service number-a unique patient identifier-enables record linkage across clinical registries and other data sources. It would be feasible to exploit this to link across further data sources (eg, trace readmission from administrative data). In fact, strategic linking of complementary registries and data sources is a "foundational architectural construct" recommendation of the US Medical Device Registries Task Force. 21 Furthermore, record linkage could be further extended using unique serial numbers of implanted devices (including prosthetic aortic valves) to device manufacturer databases to improve ongoing research, augment clinical trial follow-up after completion, and to allow traceability in case of serious fault detection. The planned role out by the FDA of a unique device identification system integrated for use with electronic health records would allow scalable crossspecialty surveillance.
22
We explored outcomes in prosthetic valves crosssectionally using 15 years of data. Moving forward, this is not a suitable approach for postmarket device surveillance, which should be dynamic, providing regular updates, to achieve superiority over existing passive reporting mechanisms. It is conceivable that signals of unexpected patterns of outcomes could have been detected earlier on. The Data Extraction and Longitudinal Trend Analysis (DELTA) network study 23 is a validated example of such a tool, which has used propensity score matching and statistical process control methodology to evaluate the safety of high-risk cardiovascular devices for perioperative binary outcomes. 13,21,24 Similar efforts for postmarket surveillance of pharmacological products are also ongoing. 25 While the methodology applied here was relatively simplistic, what we have demonstrated is that routinely collected clinical registry data can be leveraged for evaluating performance of medical devices, even when this was not a primary goal of the data collection program. With some improvements to the data collection mechanisms, this messy real-world registry, or other registries, data could be analyzed using alternative platforms.
Limitations Data Quality
Research with routinely collected health care data inevitably raises questions over data quality. Many of the data on clinical variables are of high quality, owing to the fact they are used for national governance. 16, 26 Valve-specific data, on the other hand, are not subject to similar quality management. Because the valve model data were collected as free-text inputs, more data quality issues were present than for equivalent clinical information collected using structured inputs. Data quality is expected to improve in the future, due to increased scrutiny of device monitoring. Caution must therefore be taken when interpreting the results, because there is potential for coding errors by the surgeon.
Valve Classification
Focusing surveillance on a coarsened valve grouping (ie, series) as opposed to valve models ensured that the maximum number of records would be available for analysis. This decision, while allowing us to retain more records for analysis, introduces limitations. First, different models in a series, including stented and stentless models, or different generations of the same model, might have a variable effect on outcome. For example, the latest generations of Sorin Mitroflow valves are processed with a phospholipid reduction treatment to mitigate calcification. This might lead to improved performance compared with earlier generations. Second, not all valve series are clearly delineated owing to either historical device company purchases and/or mergers or naming conventions. Similarity in naming means that valves identified to the series level but not the model level might potentially be misclassified. This is discussed further in the eAppendix in the Supplement.
Covariate Adjustment
The adjustment data used in this study derives from a national clinical registry, which is widely accepted to be superior to administrative data. 27 There was no a priori expectation of gross selection bias by valve series within valve type, nor was substantial heterogeneity observed, unlike in some other postmarket surveillance studies for cardiovascular devices. 13 However, there has been a shift in patient risk profiles over time, 28 which might confound with market availability of certain valves. We adjusted for baseline risk factors, as well for a number of clinical valve-related variables, and contrasted the change in inference with that of the unadjusted model. Another potential source of bias stems from the missing data being imputed according to a (sex-stratified) mean or mode approach; 29 however, missing data was not considered substantial. It should also be noted that the number of random effects was quite small for a frailty model. Additionally, no adjustment for institutional effects were included, which could conflate with models implanted.
Study Outcomes
In some records, patient identification was missing, which can reduce the ability to track patients. The greatest clinical limitations of this study are its relatively short follow-up and lack of other clinical outcomes.
32
The median follow-up time was 4.1 years; however, valve failure is most likely to occur later on, especially in the context of mechanical valves. In fact, only 152 surgical reinterventions were observed in the mechanical valve group. Finally, we excluded patients who had multiple surgical records within a single admission; however, there were only 34 such cases satisfying this exclusion criteria for the study.
Conclusions
The need for such postmarketing surveillance of medical devices was made clear by the Poly Implant Prothèse breast implant and other medical device scares, 3 Frailties (black filled circles) and 95% prediction intervals (black lines) by valve series for time-to-death or re-intervention as calculated for Cox random effects models (without adjustment for baseline covariates) with a time origin of 90-days. Patients who died or had a re-intervention on postoperative day 90 or before were excluded, as were patients with <90-days follow-up time. Red dashed line denotes 'no effect.' This supplementary material has been provided by the authors to give readers additional information about their work.
Supplemental Material
Using national registry data and record linkage to inform postmarket surveillance of prosthetic aortic valve models over 15-years
METHODS AND DATA: FURTHER DETAILS
Below we describe additional technical details from the Methods section on the data, data pre-processing, record linkage, and statistical methods. 3 When referring to AVR in this manuscript, we will explicitly mean surgical AVR.
Surgery
Record Linkage
To facilitate long-term monitoring of patient and valve status, we performed multiple record linkages for each patient as follows. Here, 'series' is defined as a group of valves from a single company considered similar or related (See Table S1 for groupings used). Not all valves could be classified at the model level; for example, "Edwards Lifesciences Perimount" could be one of a number of specific valves. In such a situation, we could still identify the valve manufacturer, series and (xenograft) type, which was sufficient for this study.
Indicator variables for each variable recorded were also used to capture the number of times a match was identified, and was used as the primary metric for data quality filtering.
In order to fulfill the study objectives, we needed to ensure records that were irrelevant or which featured gross inconsistencies were excluded. Therefore, we applied a second raft of exclusion criteria. We excluded records meeting the following conditions:
1. Manufacturer unidentified or recorded data matches to >1 manufacturer.
2. Series unidentified or recorded data matches to >1 valve series. For the purposes of this study, Vascutek also includes valves manufactured/supplied by Koehler Medical and AorTech. This is owing to the change in ownership of certain valve models over the study period between these companies, which complicates attribution in the classification algorithm. stopped, with the data suggesting they these records may have been misclassified.
Notes on classification
Although a great effort was invested in the development of the matching algorithms, it is conceivable that some models have been misclassified beyond the inherent input errors present, as not all valve series are clearly delineated due to either historical device company purchases/mergers or naming conventions. As an example of the former case, consider Sulzer CarboMedics, which was a former device company (part of the Sulzer Medica company). They entered into a distribution agreement with (but were later acquired by) the company Mitroflow Enterprise Ltd., which produced the Mitroflow tissue valve. It is conceivable that there was a lag between some units updating model names in their registry system and either new models coming on to the market, model renaming due to rebranding, or model numbers being updated due to iteration in the model generation. Nonetheless, as models were only analysed within series groups, we expect the results to be reasonably robust, as misclassification of models within a series should not affect the inferences. Despite enforcing data quality criteria on matches to valve manufacturer, model, series, and (xenograft) type, valves were not excluded on the basis of invalid valve size or implantation dates outside of the market availability period. In the case of the latter, this information was unavailable to us at the time of analysis for most valves. Moreover, the shelf life of mechanical valves means we cannot be certain at what point implantations might cease with particular models. We also note that some hospitals that used custom dropdown menu systems might, for example, have delayed updating the available models periodically, forcing surgeons to select the nearest appropriate model.
Study variables
For each operation, data were extracted for administrative factors, patient characteristics, comorbidities, surgical team, intra-operative factors, and postoperative outcomes. For this study we extracted data on patient age at time of 
Statistical analysis
For all analyses, data on mechanical and biological valves were analyzed separately to avoid obvious confounding by indication. Valves were compared only at the series-level. Box-and-whisker plots and bar charts were used to contrast variables between valves. Line graphs were used to display temporal trends.
The Kaplan-Meier estimator was used to construct survival curves for the time-to-event outcomes, and compared between valves using log-rank tests. There was no prima facie expectation of differences in baseline covariates between valves (within a valve type of biological or mechanical). Nonetheless, as this was an observational registry and thus patients were non-randomized, multivariable Cox proportional hazards (PH) regression models were used to adjust for potential differences. The Cox regression model assumes the hazard rate at time t for an individual i with covariate vector X i to be exp , where h 0 (t) is an arbitrary baseline hazard rate and is a parameter vector common to all patients.
5
All pre-and intra-operative variables were initially included in the multivariable Cox proportional hazards regression models. In all models, valve hemodynamics was dichotomized to regurgitation versus stenosis or mixed, and NYHA grades I and II were merged. BMI was included as a quadratic polynomial to capture the approximate U-shape association with outcome. The functional form for valve size was verified as being approximate linear in log relative hazard in each valve type group (biological and mechanical) by plotting estimates of the restricted cubic spline functions, 6 adjusted for gender and BMI. The proportional hazards assumption was assessed by the Grambsch and Therneau test. 7 The impact of any violations were assessed by graphical inspection of scaled Schoenfeld residuals plotted against time. Additionally, the model was refitted with the baseline hazard function stratified on a subset of the identified violating covariates, and the valve series effects compared to the non-stratified model. In the case of a continuous variable being identified as violating the assumption, it was categorized based on quintiles and used as a stratification variable in the aforementioned sensitivity analysis.
We extend the primary model to include adjustments for valve series. We could stratify the baseline hazard function; however, as stratum effects are modelled Time-to-event analyses were performed using the survival (version 2.39-4) and coxme (version 2.2-5) packages. 5 Restricted cubic splines were calculated using the Hmisc package (version 3.17-4).
6
Sensitivity analyses
To account for potential differences in perioperative mortality between valves, we repeated analyses without baselines covariate adjustment using a landmark of 90-days (i.e. conditional on patients having not yet experienced an event 90-days after surgery and still remaining in the risk set). Deaths occurring after 90-days will mostly be unrelated to the actual surgery, although there will still be some nondischarged patients due to major postoperative complications. A drawback of this approach is a reduction in power (through fewer events) and statistical efficiency (through smaller sample sizes).
To account for intra-series development and other potential temporal To assess whether partially classified models and models with small sample sizes affect the study results, a sensitivity analysis was performed whereby valves identified to the series level, but not model level, were excluded, and any model types with <100 valves were excluded.
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ADDITIONAL RESULTS
Study data
A total of 105,239 records met the initial inclusion criteria, and formed the dataset used for tracking surgical re-interventions. Of these records, 79,345
corresponded to an isolated AVR ± CABG with a biological or mechanical prosthesis.
A total of 9520 records were excluded based on the initial exclusion criteria, leaving 69,825 records. Multiple valve pathologies were recorded for 5133 patients (7.4%), and the most clinically relevant pathology was identified at this stage. After applying the second raft of exclusion criteria, a total of 54,866 records were left for analysis.
The greatest loss of records was at steps 1 and 2 (8, 
Valve surveillance
Kaplan-Meier curves for biological and mechanical valves for freedom from re-intervention or death are shown in Figures S9-S10 . We note that the purpose of the plots is to emphasise the heterogeneity in survivorship distributions, rather than to demarcate survival curves for individual valves. The log-rank tests indicated significant differences for both valve types (biological and mechanical both P<0.001).
To put the survival differences into a clinical context, the 10-year overall freedom from re-intervention or death rates for the Sorin Biological series and the Sorin There was some evidence of violation of the proportional hazards assumption in the Cox regression models for some covariates, as inferred by the GrambschTherneau test. 7 The effect of non-proportionality was assessed and was found not to substantially alter inferences. Therefore, the primary models were fitted without covariate stratification.
Sensitivity analyses
Of After excluding all patients who experienced an event on postoperative day 90 or before, and also patients lost to follow-up within the first 90-days (leaving n=40,741 patients in the biological group, and n=10,626 in the mechanical valve group), re-running the analysis from a time origin of 90-days yielded broadly consistent inferences ( Figure S12 ). This is consistent with results from a logistic mixed effects regression model (adjusted for logistic EuroSCORE by means of a logit transformation) for in-hospital mortality, which showed no significant systematic difference between the valves, with the exception of the Edwards Lifesciences Perimount Magna series conferring a marginally significant lower risk of in-hospital
